$OCUL insider trading
Over the last 12 months, Ocular Therapeutix insiders reported 1 buy totaling $461K and 28 sales totaling $3.4M across SEC Form 4 filings. 86% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $461K 1 event
- Sold · 12m
- $3.4M 28 events
- Events · 12m
- 29 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 86% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Notman DonaldChief Operating Officer · O | ▼ Sale | 1,099 | $10.24 | $11K | -0.3% | — |
| Aug 24, 2026 | Kaiser PeterChief Development Officer · O | ▼ Sale | 3,035 | $10.77 | $33K | -1.1% | plan |
| Aug 24, 2026 | Nayak SanjayChief Strategy Officer · O | ▼ Sale | 1,897 | $10.78 | $20K | -0.6% | plan |
| Aug 24, 2026 | Heier Jeffrey S.Chief Scientific Officer · O | ▼ Sale | 3,296 | $10.78 | $36K | -1% | plan |
| Aug 24, 2026 | Dugel PravinSee Remarks · O·D | ▼ Sale | 21,649 | $10.77 | $233K | -0.8% | plan |
| Jun 3, 2026 | Waheed NadiaChief Medical Officer · O | ▼ Sale | 14,828 | $8.27 | $123K | -4.7% | plan |
| May 26, 2026 | Dugel PravinSee Remarks · O·D | ▼ Sale | 21,156 | $8.2 | $173K | -0.8% | plan |
| May 26, 2026 | Kaiser PeterChief Development Officer · O | ▼ Sale | 2,967 | $8.2 | $24K | -1.1% | plan |
| May 26, 2026 | Heier Jeffrey S.Chief Scientific Officer · O | ▼ Sale | 3,018 | $8.2 | $25K | -0.9% | plan |
| May 26, 2026 | Nayak SanjayChief Strategy Officer · O | ▼ Sale | 1,858 | $8.2 | $15K | -0.6% | plan |
| Feb 23, 2026 | Dugel PravinSee Remarks · O·D | ▼ Sale | 20,056 | $8.28 | $166K | -0.7% | plan |
| Feb 23, 2026 | Kaiser PeterChief Development Officer · O | ▼ Sale | 2,810 | $8.28 | $23K | -1% | plan |
| Feb 23, 2026 | Heier Jeffrey S.Chief Scientific Officer · O | ▼ Sale | 3,057 | $8.28 | $25K | -0.9% | plan |
| Feb 23, 2026 | Nayak SanjayChief Strategy Officer · O | ▼ Sale | 1,759 | $8.28 | $15K | -0.5% | plan |
| Feb 20, 2026 | Waheed NadiaChief Medical Officer · O | ▼ Sale | 3,510 | $7.74 | $27K | -1.1% | plan |
| Feb 20, 2026 | LINDSTROM RICHARD L MDD | ▲ Buy | 60,229 | $7.66 | $461K | +32.3% | — |
| Feb 12, 2026 | Notman DonaldChief Operating Officer · O | ▼ Sale | 11,446 | $9.04 | $103K | -3% | — |
| Feb 12, 2026 | Nayak SanjayChief Strategy Officer · O | ▼ Sale | 10,348 | $9.04 | $94K | -3% | plan |
| Feb 12, 2026 | Dugel PravinSee Remarks · O·D | ▼ Sale | 124,882 | $9.04 | $1.1M | -4% | plan |
| Feb 12, 2026 | Waheed NadiaChief Medical Officer · O | ▼ Sale | 7,863 | $9.04 | $71K | -2.4% | plan |
| Feb 4, 2026 | Notman DonaldChief Operating Officer · O | ▼ Sale | 11,490 | $8.82 | $101K | -3% | 2 tranches |
| Nov 24, 2025 | Nayak SanjayChief Strategy Officer · O | ▼ Sale | 1,878 | $12.04 | $23K | -0.7% | plan |
| Nov 24, 2025 | Dugel PravinSee Remarks · O·D | ▼ Sale | 19,530 | $12.04 | $235K | -0.6% | plan |
| Nov 24, 2025 | Kaiser PeterChief Development Officer · O | ▼ Sale | 3,007 | $12.02 | $36K | -1.5% | plan |
| Nov 24, 2025 | Heier Jeffrey S.Chief Scientific Officer · O | ▼ Sale | 3,469 | $12.04 | $42K | -1.4% | plan |
| Nov 5, 2025 | Saroj NamrataChief Business Officer · O | ▼ Sale | 25,865 | $10.74 | $278K | -12.9% | plan |
| Oct 8, 2025 | Anderman ToddChief Legal Officer · O | ▼ Sale | 11,132 | $12.34 | $137K | -11.3% | plan |
| Oct 2, 2025 | Kaiser PeterChief Development Officer · O | ▼ Sale | 9,653 | $11.03 | $106K | -4.7% | plan |
| Oct 2, 2025 | Heier Jeffrey S.Chief Scientific Officer · O | ▼ Sale | 10,502 | $11.04 | $116K | -4% | plan |
| Sep 2, 2025 | Notman DonaldSee Remarks · O | ▼ Sale | 1,066 | $12.43 | $13K | -0.3% | — |
| Aug 25, 2025 | Kaiser PeterChief Development Officer · O | ▼ Sale | 3,011 | $12.04 | $36K | -1.5% | plan |
| Aug 25, 2025 | Nayak SanjayChief Strategy Officer · O | ▼ Sale | 1,885 | $12.04 | $23K | -0.7% | plan |
| Aug 25, 2025 | Heier Jeffrey S.Chief Scientific Officer · O | ▼ Sale | 3,063 | $12.04 | $37K | -1.2% | plan |
| Aug 25, 2025 | Dugel PravinSee Remarks · O·D | ▼ Sale | 21,494 | $12.04 | $259K | -0.7% | plan |
Every $OCUL filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Ocular Therapeutix filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $OCUL feed.